证券代码：600196 股票简称：复星医药 编号：临 2024-058 ●召开方式：视频和网络互动 ●互动网址：上证路演中心（https://roadshow.sseinfo.com/） 上海复星医药（集团）股份有限公司 关于召开 2023 年度及 2024 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ●召开时间：2024 年 5 月 17 日(星期五)下午 15:00-16:30 ●投资者可于 2024 年 5 月 10 日(星期五)至 5 月 16 日(星期四)16:00 期间登录 上证路演中心网站首页点击"提问预征集"栏目进行提问，或将问题以电子邮件形 式发送至本公司投资者关系邮箱 ir@fosunpharma.com。本公司将于业绩说明会上就 投资者普遍关注的问题进行回答。 上海复星医药（集团）股份有限公司（以下简称"本公司"）于 2024 年 3 月 27 日披露 2023 年年度报告，并于 2024 年 4 月 30 日披露 2024 年第一季度报告。为 ...

证券代码：600196 股票简称：复星医药 编号：临 2024-057 上海复星医药（集团）股份有限公司 关于控股子公司获药品注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海 重庆药友制药有限责任公司自主研发的阿立哌唑口崩片（以下简称"该新药"）用 于治疗精神分裂症的上市注册申请于近日获国家药品监督管理局批准。 二、该新药的基本情况 药品通用名称：阿立哌唑口崩片 剂型：片剂 规格：5mg、10mg、15mg 三、该新药的研究和上市情况 该新药为本集团（即本公司及控股子公司/单位，下同）自主研发的化学药品， 主要用于治疗精神分裂症。 截至 2024 年 3 月，本集团现阶段针对该新药累计研发投入约为人民币 1,035 万 元（未经审计）。 截至本公告日，除该新药外，于中国境内（不包括港澳台地区，下同）已获批 上市的其他阿立哌唑制剂主要包括浙江大冢制药有限公司的安律凡® （阿立哌唑 片）、成都康弘药业集团股份有限公司的博思清（阿立哌唑口崩 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年4月30日 狀態: 新提交 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2024年5月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

证券代码：600196 股票简称：复星医药 编号：临 2024-056 上海复星医药（集团）股份有限公司 截至本公告日，于全球范围内尚无同类联合用药治疗方案获批用于治疗胃癌。 1 关于控股子公司获美国 FDA 药品临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海 复宏汉霖生物技术股份有限公司及其控股子公司（以下合称"复宏汉霖"）于近日 收到美国 FDA（即美国食品药品监督管理局）关于同意 HLX22（即抗人表皮生长因子 受体-2（HER2）人源化单克隆抗体注射液）联合曲妥珠单抗及化疗一线治疗 HER2 阳 性的晚期胃癌（以下简称"该治疗方案"）开展临床试验的函。复宏汉霖拟于条件 具备后于美国开展该治疗方案的 III 期临床试验。 二、该治疗方案所涉药品的研究情况 该治疗方案中所涉 HLX22 为本集团（即本公司及控股子公司/单位，下同）自 AbClon, Inc.许可引进，并后续自主研发的新型靶向 HER2 的单克隆抗体，拟用于胃 ...

证券代码：600196 证券简称：复星医药 公告编号：2024-055 实际回购价格区间 0 元/股~0 元/股 根据中国证券监督管理委员会《上市公司股份回购规则》、《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等相关规定，在回购期间，上市公司应 当于每个月的前 3 个交易日内公告截至上月末的回购进展情况。现将回购方案的 实施进展情况公告如下：自 2024 年 3 月 26 日（即董事会审议通过回购方案之日） 起至 2024 年 4 月 30 日期间，于回购方案下，本公司暂未回购股份。 上海复星医药（集团）股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/3/27 | | --- | --- | | 回购方案实施期限 | 2024/3/26~2024/9/25 （含首尾两日） | | 预计回购金额 | 人民币 10,000 万元~20,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划 ...

Financial Performance - The group's operating revenue for Q1 2024 was RMB 10.16 billion, a decrease of 6.56% compared to the same period last year[3]. - Net profit attributable to shareholders of the listed company was RMB 609.73 million, down 38.22% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 608.54 million, a decrease of 33.81% year-on-year[3]. - Basic and diluted earnings per share were both RMB 0.23, reflecting a decline of 37.84% year-on-year[3]. - The decline in revenue was primarily due to a significant drop in sales of COVID-related products compared to Q1 2023[4]. - The acquisition of Cenexi by Gland Pharma impacted the financial results due to amortization and operational losses[5]. - Operating profit for Q1 2024 was RMB 1,021,364,060.98, down from RMB 1,427,139,292.41 in Q1 2023, reflecting a decline of 28.5%[25]. - Net profit for Q1 2024 was RMB 786,221,155.86, compared to RMB 1,114,254,110.16 in Q1 2023, representing a decrease of 29.4%[25]. - The company reported a significant increase in investment income of RMB 335,558,032.75 in Q1 2024, compared to RMB 765,904,456.45 in Q1 2023, indicating a decline of 56.2%[25]. Assets and Liabilities - The group's total assets at the end of the reporting period were RMB 113.75 billion, an increase of 0.24% from the end of the previous year[4]. - Total liabilities as of March 31, 2024, were RMB 56,210,115,353.13, slightly down from RMB 56,853,344,377.17 as of December 31, 2023[24]. - Current liabilities totaled RMB 33,602,092,132.74 as of March 31, 2024, compared to RMB 33,757,583,537.82 at the end of 2023, indicating a decrease of 0.5%[24]. - Non-current liabilities amounted to RMB 22,608,023,220.39, down from RMB 23,095,760,839.35 as of December 31, 2023, a reduction of 2.1%[24]. - As of March 31, 2024, total current assets amounted to RMB 33.84 billion, slightly increasing from RMB 33.79 billion as of December 31, 2023[23]. - Total non-current assets as of March 31, 2024, were RMB 79.91 billion, compared to RMB 79.68 billion as of December 31, 2023[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 272,884[8]. - The largest shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., holds 886,315,955 shares, accounting for 33.17% of the total voting rights[8]. - HKSCC Nominees Limited holds 551,374,315 shares, representing 20.63% of the total[8]. - The total shares held by the top ten shareholders amount to 1,586,000,000 shares, which is approximately 60.00% of the total shares[9]. - The controlling shareholder, Fosun High Technology, holds a total of 957,849,455 shares, which is about 35.84% of the total shares[10]. - The company has not disclosed any related party transactions or concerted actions among the top shareholders[9]. Research and Development - The company launched a lyophilized rabies vaccine and an automated chemiluminescence immunoassay analyzer, both of which received regulatory approval in China[13]. - The company’s biosimilar trastuzumab received FDA approval for multiple cancer treatments, marking it as the first domestically developed biosimilar approved in China, the EU, and the US[13]. - Multiple products are in critical clinical or approval stages, including OP 0595 for treating infections and additional indications for the biosimilar Adalimumab[14]. - Research and development expenses for Q1 2024 were RMB 829,567,181.62, a decrease from RMB 968,872,153.04 in Q1 2023, reflecting a reduction of 14.4%[25]. - Research and development expenses for Q1 2024 were RMB 20.75 million, compared to RMB 10.69 million in Q1 2023, showing an increase of approximately 94%[31]. Cash Flow and Investments - Cash flow from operating activities was RMB 917 million, reflecting a year-on-year increase of 5.05%[12]. - The company approved a share repurchase plan with a total amount not less than RMB 100 million and not exceeding RMB 200 million, with a repurchase price not exceeding RMB 30 per share[21]. - The company received ¥7,989,226,244.59 in cash from borrowings during Q1 2024, an increase from ¥6,883,841,990.77 in Q1 2023[28]. - Cash flow from operating activities generated a net amount of approximately ¥9.93 million in Q1 2024, a significant decrease from ¥371.36 million in Q1 2023[33]. - Cash flow from investing activities showed a net outflow of approximately ¥447.22 million in Q1 2024, compared to an outflow of ¥73.58 million in Q1 2023[33]. Strategic Initiatives - The company established a strategic cooperation and exclusive licensing agreement with Sermonix Pharmaceuticals, planning to develop and commercialize at least two indications for ER+/HER2- breast cancer in China and Hong Kong, Macau, and Taiwan[18]. - The company signed an agreement to jointly establish a private equity investment fund in Shenzhen with a total commitment of RMB 5 billion, with the company contributing RMB 1.5 billion, holding a 30% share[18]. - The company plans to explore innovative payment models for high-value innovative drugs, as demonstrated by the launch of a new payment scheme for a product in collaboration with a joint venture[17].

Financial Performance - The company reported a total revenue of RMB 10.16 billion for Q1 2024, a decrease of 6.56% year-on-year[5]. - Net profit attributable to shareholders was RMB 609.73 million, down 38.22% compared to the same period last year[5]. - The basic and diluted earnings per share were both RMB 0.23, reflecting a decline of 37.84% year-on-year[5]. - The company achieved operating revenue of 10.157 billion RMB in Q1 2024, a decrease of 6.56% year-on-year, primarily due to a significant drop in revenue from COVID-related products compared to the previous year[12]. - Net profit attributable to shareholders was 610 million RMB, a year-on-year decrease of 38.22%, largely impacted by reduced sales of COVID-related products and amortization from the acquisition of Cenexi[13]. - Operating profit for Q1 2024 was ¥1,021,364,060.98, down 28.5% from ¥1,427,139,292.41 in Q1 2023[23]. - The company reported a net profit margin of 7.75% in Q1 2024, down from 10.24% in Q1 2023[23]. - The total profit for the current period is approximately ¥329.55 million, compared to ¥410.08 million in the previous period, reflecting a decrease of about 19.6%[30]. - The net profit for the current period is approximately ¥329.55 million, an increase from ¥305.40 million in the previous period, indicating a growth of about 7.9%[30]. Cash Flow and Assets - The net cash flow from operating activities increased by 5.05% to RMB 917.31 million[5]. - The company reported a net cash flow from operating activities of 917 million RMB, an increase of 5.05% year-on-year[13]. - In Q1 2024, the company reported operating cash inflow of ¥10.30 billion, a decrease of 13.2% from ¥11.87 billion in Q1 2023[25]. - The company experienced a significant decline in cash inflow from investment activities, totaling ¥376.94 million, down 78.1% from ¥1.72 billion in Q1 2023[25]. - The net cash flow from financing activities was ¥98.64 million, a decrease of 65.0% from ¥281.97 million in Q1 2023[26]. - As of March 31, 2024, the company's total current assets amounted to CNY 33.84 billion, showing a slight increase from CNY 33.79 billion at the end of 2023[21]. - The company's total cash inflow from financing activities was approximately ¥4.56 billion, compared to ¥6.71 billion in the previous period, indicating a decrease of about 32%[32]. Shareholder Information - The largest shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., holds 886,315,955 A shares, representing 33.17% of total shares[9]. - The total number of common stock shareholders at the end of the reporting period was 272,884[8]. - The company’s total shares held by the top ten shareholders accounted for approximately 35.84% of total shares[9]. Product Development and Innovation - The company launched a self-developed lyophilized rabies vaccine and the F-i6000 fully automated chemiluminescence immunoassay analyzer, both of which received approval for market entry in China[13]. - The company is focusing on innovation and product development as part of its strategic transformation[13]. - The company's self-developed biosimilar trastuzumab (Hanquyou) has been approved by the FDA for multiple indications, marking it as the first domestically produced biosimilar approved in China, the EU, and the US[14]. - The Ion bronchial navigation system has received approval from the National Medical Products Administration, enabling more precise and minimally invasive lung cancer diagnostics and treatments[15]. - The company has initiated two Phase III clinical studies for OP0595 in combination with antibiotics targeting adult Gram-negative bacterial infections in China[15]. - The company has received acceptance for four additional indications for its biosimilar adalimumab (HLX04) from the National Medical Products Administration[15]. - The company has established a strategic partnership with Sermonix to develop and commercialize lasofoxifene for at least two ER+/HER2- breast cancer indications in China and Hong Kong[18]. Strategic Initiatives - The company has signed an agreement to establish a Shenzhen biopharmaceutical industry fund with a total commitment of CNY 5 billion, of which the company will contribute CNY 1.5 billion[18]. - The company plans to repurchase shares with a total amount not less than CNY 100 million and not exceeding CNY 200 million within six months, with a maximum price of CNY 30 per share[20]. Asset and Equity Changes - Total assets at the end of the reporting period were RMB 113.75 billion, a slight increase of 0.24% from the previous year[5]. - The company reported a total equity attributable to shareholders of RMB 46.35 billion, an increase of 1.45% year-on-year[5]. - Total liabilities decreased to ¥56,210,115,353.13 from ¥56,853,344,377.17, a reduction of 1.14%[22]. - The company's long-term equity investments increased to CNY 24.11 billion as of March 31, 2024, compared to CNY 23.92 billion at the end of 2023[21]. - The company's goodwill remained stable at CNY 10.85 billion as of March 31, 2024, compared to CNY 10.85 billion at the end of 2023[21].

证券代码：600196 股票简称：复星医药 编号：临 2024-052 上海复星医药（集团）股份有限公司 关于控股子公司获药品注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司沈阳 红旗制药有限公司自主研发的环丝氨酸胶囊（以下简称"该新药"）用于对该药敏 感的结核菌引起的且经一线抗结核药（如链霉素、异烟肼、利福平和乙胺丁醇）治 疗效果不佳的活动性肺结核和肺外结核（包括肾结核）治疗的上市注册申请于近日 获国家药品监督管理局批准。 二、该新药的基本情况 药品通用名称：环丝氨酸胶囊 剂型：胶囊剂 规格：0.25g 注册分类：化学药品 3 类 上市许可持有人/药品生产企业：沈阳红旗制药有限公司 药品批准文号：国药准字 H20243531 三、该新药的研究和上市情况 该新药为本集团（即本公司及控股子公司/单位，下同）自主研发的化学药品， 主要用于对该药敏感的结核菌引起的且经一线抗结核药（如链霉素、异烟肼、利福 平和乙胺丁醇）治疗效果不佳的活动性肺结核 ...

Financial Performance - The company achieved a revenue of RMB 41,249 million in 2023, a decrease of 5.85% compared to RMB 43,811 million in 2022[8]. - The net profit attributable to shareholders was RMB 2,399 million, down from RMB 3,737 million in the previous year[8]. - The company's earnings per share decreased to RMB 0.90, a decline of 37.06% compared to 2022, primarily due to the drop in net profit attributable to shareholders[38]. - The company's cash and bank balances decreased to RMB 13,694 million from RMB 16,241 million[8]. - The company's total assets increased to RMB 113,431 million, up from RMB 107,113 million in 2022[8]. - The company's EBITDA for 2023 was RMB 7,720 million, a decrease of 3.99% from RMB 8,041 million in 2022, resulting in an interest coverage ratio of 5.61 times compared to 7.94 times in 2022[63]. - Net profit for the reporting period decreased by 26.48% to RMB 2,907 million, with net profit margins of 7.05% in 2023 compared to 9.03% in 2022[46]. - Total debt as of December 31, 2023, was RMB 32,574 million, an increase from RMB 29,116 million in 2022, with a debt-to-asset ratio of 28.72%[49][52]. Research and Development - Research and development expenses totaled RMB 4,346 million, an increase of 1.02% year-on-year[14]. - The group has 20 innovative drugs/biosimilars approved for clinical trials during the reporting period, indicating a robust pipeline[19]. - The company is enhancing its digital capabilities in drug research and development, including the establishment of a quantitative decision-making system for AI drug development[32]. - The company is focusing on lean R&D and operational efficiency, enhancing its core therapeutic areas and integrating internal and external R&D resources to improve early-stage R&D and CMC capabilities[91]. - The group has initiated an "ESG Culture Month" to deepen employee understanding of compliance and risk management[97]. - The establishment of the Scientific Advisory Board (SAB) aims to enhance R&D efficiency and provide strategic guidance, consisting of 12 internationally renowned experts[146]. - The group is actively exploring cutting-edge technologies such as tumor vaccines and AI drug development to enhance core R&D capabilities[146]. Product Development and Approvals - In 2023, the group received approval for 8 indications of 6 innovative drugs, including the first PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in China[15]. - The company has advanced its pipeline with 5 products and 7 indications entering the pre-market approval stage during the reporting period[79]. - The company is actively pursuing market expansion through the development of new therapies and technologies in oncology and infectious diseases[108]. - The innovative PD-1 inhibitor, Hanshuang (Surulintan injection), received approval for two new indications in China, becoming the first targeted PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) globally[123]. - The company has received conditional approval from the National Medical Products Administration for the registration of Yikaida (Acalabrutinib Injection) for adult patients with relapsed/refractory large B-cell lymphoma (r/r LBCL) in June 2023[109]. - The company has received approval for the marketing of Tenapanor for constipation-predominant irritable bowel syndrome in Hong Kong[103]. Market Expansion and Sales - The group expanded its sales network in Africa, covering over 40 countries and regions, and is constructing a local drug manufacturing and supply facility in Côte d'Ivoire[23]. - The company has established a marketing network covering over 100 countries, with direct sales revenue increasing to 78%[83]. - The company is enhancing its digital management and user operation capabilities to provide comprehensive services in emerging markets, including registration, circulation, and post-market safety monitoring[95]. - The company is actively pursuing new strategies to enhance its competitive edge in the healthcare market through product diversification[163]. - The company is exploring strategic partnerships to enhance its market reach and operational efficiency, particularly in the Asia-Pacific region[166]. Operational Efficiency - The company plans to enhance its global layout and strengthen operational efficiency under the "4IN" strategy[13]. - The group established a comprehensive manufacturing center and three active pharmaceutical ingredient production bases to enhance cost competitiveness and operational efficiency[25]. - The company is focusing on core therapeutic areas and improving operational efficiency through lean management and resource integration[24]. - The company is committed to ensuring the accuracy of its financial and operational reporting as it navigates the competitive pharmaceutical landscape[105]. - The company is investing in advanced manufacturing technologies to improve product quality and reduce production costs, ensuring competitive pricing in the market[166]. Financial Management - The company optimized its debt structure and financing costs, ensuring long-term sustainable development through diversified financing channels[190]. - The company registered and issued RMB 8 billion in corporate bonds and secured a syndicated loan of €230 million during the reporting period[190]. - The sales expense ratio increased to 23.54%, up 2.61 percentage points year-on-year, primarily due to decreased revenue from COVID-related products and increased costs in overseas markets[194]. Corporate Social Responsibility - The company continues to focus on innovation and sustainable development as part of its corporate social responsibility[12]. - The company is prioritizing sustainability in its operations, aiming to reduce its carbon footprint by 20% over the next five years[167].

上海复星医药（集团）股份有限公司 关于参与设立的投资基金完成私募投资基金备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 2023 年 3 月 30 日，上海复星医药（集团）股份有限公司（以下简称"本公司"） 控股子公司/企业上海复毓晟健企业管理合伙企业（有限合伙）（以下简称"复毓晟 健"）、宁波复瀛投资有限公司（以下简称"宁波复瀛"）与其他 2 方投资人签订 《安吉复毓承祥创业投资合伙企业（有限合伙）有限合伙合同》等，以共同出资设 立安吉复毓承祥创业投资合伙企业（有限合伙）（以下简称"安吉创新器械基金"）； 同日，本公司控股子公司/企业复毓晟健、宁波复瀛与其他 3 方投资人签订《徐州复 毓彭泰创业投资合伙企业（有限合伙）有限合伙合同》等，以共同出资设立徐州复 毓彭泰创业投资合伙企业（有限合伙）（以下简称"徐州创新器械基金"）。安吉 创新器械基金、徐州创新器械基金为平行基金，该等平行基金将在同时满足各自决 策机制约定的条件下共同实施对外投资。安吉创新器械基金、徐州创新器械基金设 立完成后，将聘请本公司控股子 ...